SiNtx Technologies Inc. (SINT)
SINT trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1269026/000149315226011924/0001493152-26-011924-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SINT on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001269026 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0M |
| Net income | -$10.4M |
| Operating income | -$10.7M |
| Net margin | -1018.1% |
| Operating margin | -1053.1% |
| Revenue growth | -64.7% |
| Cash | $4.1M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Despite the actions undertaken by management to improve liquidity and operating costs including increased commercial activity, cost and pricing improvement initiatives, commercialization of newly cleared medical products, equity financing activities, proceeds from warrant exercises subsequent to quarter-end, and other working capital initiatives management has concluded that substantial doubt remains regarding the Co" | 10-Q 2026-11-05 |
| Cash and burn | $2.0M cash; operating cash flow -$2.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 7,558,241 (2026-11-02); 3,851,956 a year earlier; 4,259,758 three years earlier. 3y figure adjusted for splits (1-for-200 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-200 on 2024-05-28 | Source 2024-05-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-13 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-05-27 |
| Auditor | Tanner LLP, Lehi, Utah, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $300K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.2M | -$1.6M | -$1.4M | $2.0M | $55K | $3.3M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $452K | -$2.7M | -$2.8M | $3.6M | $102K | $1.3M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $380K | -$2.8M | -$2.5M | $1.9M | $106K | $1.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $290K | -$2.2M | -$2.3M | $4.1M | $7K | $1.0M | 10-K 2026-03-20 |
| Q3 2025 2025-09-30 | $208K | -$3.5M | -$2.5M | $6.3M | $59K | $1.3M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $151K | -$2.3M | -$2.4M | $4.3M | $109K | $1.9M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $369K | -$2.3M | -$1.3M | $6.5M | $131K | $2.6M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $542K | -$1.7M | -$1.1M | $3.6M | $32K | $2.9M | 10-K 2026-03-20 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-13 |
| Latest annual report | 10-K | 2026-03-20 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-10-30 |
Source: SEC EDGAR submissions feed, 662 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.8% |
| 1 month | -35.0% |
| 3 months | -21.3% |
| Year to date | -65.2% |
| 1 year | -56.0% |
| From 52-week high | -68.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FEMY | Femasys Inc. | $1.28 | -8.57% | $11.1M |
| PLSM | Pulsenmore Ltd. | $1.41 | +2.17% | $9.2M |
| AEMD | Aethlon Medical Inc. | $5.01 | -5.29% | $8.1M |
| DRIO | DarioHealth Corp. | $1.15 | -8.73% | $13.0M |
| GUTS | Fractyl Health Inc. | $0.9918 | +9.76% | $13.2M |
| ARAY | Accuray Incorporated | $2.55 | -8.93% | $7.7M |
| PAVM | PAVmed Inc. | $1.75 | +7.36% | $14.0M |
| CNSY | Cerenome Inc. Common Stock | $0.7148 | -24.77% | $7.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier